Search Results

InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGeneron’s cell therapy for treating partial-thickness rotator cuff tears.

InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA).

InGeneron, Inc., a clinical stage biotechnology company, announces a critical in-depth analysis of the results from a 480-patient Phase III knee osteoarthritis (OA) trial that was recently published in the Journal Nature Medicine on November 2nd, 2023.

InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a newly released study, titled “The composition of adipose-derived regenerative cells isolated from lipoaspirate using a novel point of care system does not depend on the subject’s individual age, sex, body mass index and ethnicity”, published in the Journal Cells on December 21, 2022.

InGeneron, Inc., a clinical stage biotechnology company, announced that the American Medical Association’s Current Procedural Terminology Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell therapy for partial thickness rotator cuff tears.

InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications.

InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs.

InGeneron, Inc. today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, utologous, adipose derived regenerative cells (UA-ADRCs).

InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.

InGeneron reports positive top-line data from its clinical lead program in rotator cuff tendinopathy paving the way for a pivotal study in 2019.